PMID- 36289520
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221030
IS  - 2162-3619 (Print)
IS  - 2162-3619 (Electronic)
IS  - 2162-3619 (Linking)
VI  - 11
IP  - 1
DP  - 2022 Oct 26
TI  - Recall of reactive cutaneous capillary endothelial proliferation (RCCEP) induced 
      by stereotactic body radiation therapy (SBRT) in a patient with lung squamous 
      cell carcinoma.
PG  - 78
LID - 10.1186/s40164-022-00336-4 [doi]
LID - 78
AB  - Camrelizumab (SHR-1210) is a humanized IgG4 monoclonal anti-programmed cell death 
      protein 1 (PD-1) antibody that has been shown to inhibit the binding of PD-1 to 
      PD-L1, thereby blocking the immune escape of various types of cancer, including 
      lung squamous cell carcinoma (LSCC). Reactive cutaneous capillary endothelial 
      proliferation (RCCEP) is the most common adverse event in camrelizumab-treated 
      patients. Here, we introduce a case of LSCC with recall RCCEP induced by 
      stereotactic body radiation therapy (SBRT). A 76-year-old LSCC patient developed 
      RCCEP when he received camrelizumab and chemotherapy. After discontinuing 
      camrelizumab treatment, the RCCEP lesions spontaneously regressed and fell off. 
      However, when the patient received subsequent SBRT, the RCCEP occurred again at 
      the same sites. This case may provide clues for additional study of the immune 
      reactivation effect of SBRT or the underlying mechanism of RCCEP.
CI  - (c) 2022. The Author(s).
FAU - Ma, Rong
AU  - Ma R
AD  - Department of Radiation Oncology, General Hospital of Ningxia Medical University, 
      Ningxia, 750004, Yinchuan, China.
AD  - Cancer Institute, Ningxia Medical University, Ningxia, 750004, Yinchuan, China.
FAU - Wang, Jia-Lin
AU  - Wang JL
AD  - Department of Radiation Oncology, General Hospital of Ningxia Medical University, 
      Ningxia, 750004, Yinchuan, China.
AD  - Cancer Institute, Ningxia Medical University, Ningxia, 750004, Yinchuan, China.
FAU - Wang, Yan-Yang
AU  - Wang YY
AD  - Department of Radiation Oncology, General Hospital of Ningxia Medical University, 
      Ningxia, 750004, Yinchuan, China. fdwyy1981@hotmail.com.
AD  - Cancer Institute, Ningxia Medical University, Ningxia, 750004, Yinchuan, China. 
      fdwyy1981@hotmail.com.
LA  - eng
GR  - 82060433/National Natural Science Foundation of China/
PT  - Letter
DEP - 20221026
PL  - England
TA  - Exp Hematol Oncol
JT  - Experimental hematology & oncology
JID - 101590676
PMC - PMC9607856
OTO - NOTNLM
OT  - Lung cancer
OT  - Reactive cutaneous capillary endothelial proliferation (RCCEP)
OT  - Recall
OT  - Stereotactic body radiation therapy (SBRT)
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2022/10/28 06:00
MHDA- 2022/10/28 06:01
PMCR- 2022/10/26
CRDT- 2022/10/27 00:19
PHST- 2022/07/02 00:00 [received]
PHST- 2022/10/10 00:00 [accepted]
PHST- 2022/10/27 00:19 [entrez]
PHST- 2022/10/28 06:00 [pubmed]
PHST- 2022/10/28 06:01 [medline]
PHST- 2022/10/26 00:00 [pmc-release]
AID - 10.1186/s40164-022-00336-4 [pii]
AID - 336 [pii]
AID - 10.1186/s40164-022-00336-4 [doi]
PST - epublish
SO  - Exp Hematol Oncol. 2022 Oct 26;11(1):78. doi: 10.1186/s40164-022-00336-4.